Filing Details

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

 

Nascent Biotech Inc.

(Name of Issuer)

 

Common Stock, $0.001 Par Value

(Title of Class of Securities)

 

63108Q101

(CUSIP Number)

 

Lowell Holden, CFO

631 US Hwy1 Suite 407

N Palm Beach, Fl 33408

(612) 961-5656

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

April 14, 2023

(Date of Event which Requires Filing of this Statement)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

SCHEDULE 13D 

 

CUSIP No. 63108Q101

 

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   Robert D. Burke, MD
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*    (a) ☐ (b) ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS (See Instructions)   PF
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)    ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION   United States

 

NUMBER OF  SHARES  BENEFICIALY  OWNED BY  EACH   REPORTING   PERSON   WITH	7	SOLE VOTING POWER    21,272,889
	8	SHARED VOTING POWER    0
	9	SOLE DISPOSITIVE POWER    21,272,889
	10	SHARED DISPOSITIVE POWER    0

 

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    21,272,889
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)   ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    Approximately 16.7% based on 127,330,722 common shares outstanding
14	TYPE OF REPORTING PERSON (See Instructions)    IN

 

2

 

 

Item 1. Security and Issuer

 

This Statement relates to common shares with par value of $0.001 of Nascent Biotech Inc. (the “Issuer”). The principal executive offices of the Issuer at located 631 Hwy1, Suite 407, N Palm Beach, FL 33408.

 

Item 2. Identity and Background

 

	(a)	Name: Robert D. Burke, MD
	(b)	Residence or business address: 844 Harbourisles Place, North Palm Beach, Florida 33410
	(c)	Principal Occupation or Employment: Physician
	(d)	During the last five years Dr. Robert D. Burke has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
	(e)	During the last five years, Dr. Robert D. Burke was not a party to any civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
	(f)	Dr. Burke is a citizen of the United States

 

Item 3. Source and Amount of Funds or Other Considerations

 

Dr. Burke used approximately $4,037,783 USD in the aggregate to purchase the Common Shares reported in this Schedule 13D. The source of the funds used to acquire the Common Shares from the previous owner are the personal funds of Dr. Burke.

 

Item 4. Purpose of Transaction

 

Dr. Burke acquired  no common shares of the Issuer through a private Common Stock Purchase Agreement for investment purposes in the ordinary course of business. 

 

Item 5. Interest in Securities of the Issuer

 

The aggregate number and percentage of common shares of the Issuer beneficially owned by Dr. Burke is 21,272,889 common shares, or approximately 16.7% of the Issuer, based on 127,330,722 common shares outstanding as of the March 20, 2023 as confirmed with the Issuer directly.

 

Dr. Burke has the sole power to vote or direct the vote, and to dispose or direct the disposition, of 21,272,889 shares of common stock of the Issuer.

 

Other than as described in Item 3 above, Dr. Burke has not affected any transaction in the shares of common stock of the Issuer in the past sixty days.

 

No person, other than Dr. Burke, is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the 21,272,889 shares of common stock of the Issuer.

 

3

 

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

 

Except as set forth above or set forth in the exhibits, there are no contracts, arrangements, understandings or relationships between Reporting Persons and any other person with respect to any securities of the Issuer.

 

Item 7. Material to Be Filed as Exhibits

 

None

 

4

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: April 14, 2023	/s/ Robert D Burke MD
	Signature
	Robert D. Burke, MD
	Name/Title

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

 

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

 

5